Source-grounded facts extracted from AMGEN INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
AMGEN INC shareholders rejected Stockholder Proposal to Require an Independent Board Chairman at the 2026-05-19 meeting.
“Item 4 - Stockholder Proposal to Require an Independent Board Chairman The stockholder proposal to require an independent board chairman was not approved.”
AMGEN INC shareholders approved Ratification of Selection of Independent Registered Public Accountants at the 2026-05-19 meeting.
“Item 3 - Ratification of Selection of Inde pendent Re gistered Public Accountants Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2026.”
AMGEN INC shareholders approved Advisory Vote to Approve Our Executive Compensation at the 2026-05-19 meeting.
“Item 2 - Advisor y Vote to A pprove Our Executive Compensation The advisory vote to approve our executive compensation was approved.”
AMGEN INC shareholders approved Election of Directors at the 2026-05-19 meeting.
“Item 1 - Election of Directors Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.”
Thomas Dittrich was appointed as Executive Vice President and Chief Financial Officer at AMGEN INC.
“Effective September 1, 2026, he will serve as Executive Vice President and Chief Financial Officer of the Company.”
Peter H. Griffith departed as Executive Vice President and Chief Financial Officer at AMGEN INC.
“On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.”
AMGEN INC reported the three months ended March 31, 2026 results: revenue $8.6 billion, EPS $3.34 (GAAP), $5.15 (Non-GAAP).
“deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: • For the first quarter, total revenues increased 6% to $8.6 billion in comparison to the first quarter of 2025. ◦ Produ ct sales grew 4% , driven by 9% volume growth, partially offset by 2% lower net selling price and 2% from lower inventory”
AMGEN INC entered into Officer's Certificate valued at $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031, $1,750,000, (effective 2026-02-19).
“On February 17, 2026, Amgen Inc. (the “Company”) issued and sold $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031 (the “2031 Notes”), $1,750,000,000 aggregate principal amount of the Company’s 4.850% Senior Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of the Company’s 5.500% Senior Notes due 2046 (the “2046 Notes”) and $750,000,000 aggregate principal amount of the Company’s 5.650% Senior Notes due 2056 (the “2056 Notes” and, together with the 2031 Notes, the 2036 Notes and the 2046 Notes, the “Notes”).”
AMGEN INC terminated License and Collaboration Agreement with Kyowa Kirin Co., Ltd. (effective 2026-01-30).
“On January 30, 2026, Amgen Inc. (the “ Company ”) entered into a Termination Agreement (the “ Termination Agreement ”) with Kyowa Kirin Co., Ltd. (“ Kyowa Kirin ”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “ License and Collaboration Agreement ”).”
AMGEN INC reported first quarter 2024 results: revenue $7.4 billion, EPS $3.96.
“For the first quarter, total revenues increased 22% to $7.4 billion in comparison to the first quarter of 2023.”
AMGEN INC reported financial results for the fourth quarter and full year 2023.
“Fourth Quarter 2023 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures”
David M. Reese changed role as Executive Vice President and Chief Technology Officer at AMGEN INC.
“David M. Reese, M.D., will transition from Executive Vice President, Research and Development to Executive Vice President and Chief Technology Officer, a newly created executive officer position, responsible for accelerating the use of technology and artificial intelligence (AI) across all facets of Amgen Inc.”
James Bradner was appointed as Executive Vice President, Research and Development, and Chief Scientific Officer at AMGEN INC.
“James Bradner, M.D., has been hired as the Company’s Executive Vice President, Research and Development, and Chief Scientific Officer, an executive officer position.”
AMGEN INC reported third quarter of 2023 results: revenue $6.9 billion.
“of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad innovative portfolio." Key results include: • Total revenues increased 4% to $6.9 billion in comparison to the third quarter of 2022, resulting from a 5% increase in product sales. Produ ct sales growth was driven by 11% volume growth, partially offset by 3% lower net”
AMGEN INC completed an acquisition involving Horizon Therapeutics plc for $116.50 in cash (closed 2023-10-06).
“of 11:59 p.m. New York City time on October 5, 2023, the business day prior to the occurrence of the Effective Time (the “ Scheme Record Time ”), obtained the right to receive $116.50 in cash in exchange for each Horizon Share (the “ Consideration ”). In respect of the Horizon Shares issued and outstanding as of the Scheme Record Time, Amgen paid an aggregate”
AMGEN INC incurred term loan of $4 billion with Citibank, N.A., as administrative agent, Bank of America, N.A., as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd., as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd., as documentation agents.
“On October 6, 2023, Amgen borrowed $4 billion under the Term Loan Credit Agreement”
Linda H. Louie changed role as Vice President, Finance at AMGEN INC.
“Linda H. Louie, the Company’s current CAO, has served in this role since July 2020, and effective August 14, 2023, as part of the Company’s leadership development activities, Ms. Louie will move to the role of the Company’s Vice President, Finance, with responsibility for corporate financial planning and analysis, and will step down as the Company’s Chief Accounting Officer.”
Matthew C. Busch was appointed as Vice President, Finance and Chief Accounting Officer at AMGEN INC.
“On August 1, 2023, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Matthew C. Busch, age 49, to serve as the Company’s Vice President, Finance and Chief Accounting Officer (“CAO”), effective August 14, 2023.”
AMGEN INC reported the second quarter of 2023 results: revenue $7.0 billion, EPS $5.00.
“shared today illustrates the rapid progress we are making in advancing our pipeline of potential first-in-class medicines." Key results include: • Total revenues increased 6% to $7.0 billion in comparison to the second quarter of 2022, resulting from a 6% increase in product sales. Produ ct sales growth was driven by 11% volume growth, partially offset by 2% lower”
AMGEN INC shareholders approved Ratification of Selection of Independent Registered Public Accountants at the 2023-05-19 meeting.
“Ernst & Young LLP was ratified as the Company’s independent registered public accountants for the fiscal year ending December 31, 2023.”
AMGEN INC shareholders approved Advisory Vote to Approve Our Executive Compensation at the 2023-05-19 meeting.
“The advisory vote to approve our executive compensation was approved.”
AMGEN INC shareholders approved Advisory Vote on the Frequency of Future Stockholder Advisory Votes to Approve Executive Compensation at the 2023-05-19 meeting.
“One year was selected for the advisory vote on the frequency of future stockholder advisory votes to approve executive compensation based upon the following votes: One Year: 390,912,836 Two Years: 888,684 Three Years: 5,869,436 Abstain: 816,032 Broker Non-Votes: 64,052,659”
AMGEN INC shareholders approved Election of Directors at the 2023-05-19 meeting.
“Each of the following 13 nominees for director were elected to serve a one-year term expiring at the Company’s 2024 annual meeting of stockholders and until his or her successor is elected and qualified, or until his or her earlier retirement, resignation, disqualification, removal or death.”
AMGEN INC reported three months ended March 31, 2023 results: revenue $6.1 billion, EPS $5.28.
“Key results include: • Total revenues decreased 2% to $6.1 billion in comparison to the first quarter of 2022, resulting from lower Other Revenue from our COVID-19 manufacturing collaboration, partially offset by a 2% increase in product sales. Produ ct sales growth was driven by 14% volume growth, partially offset by 5% lower net selling price, 3% unfavorable changes to estimated sales deductions, 2% lower inventory levels and 2% negative impact from foreign exchange. Excluding the 2% negative impact of foreign exchange on product sales, total revenues were largely unchanged from Q1 2022. ◦ Volume growth of 14% included double-digit volume growth from EVENITY ® (romosozumab-aqqg), BLINCYTO ® (blinatumomab), Nplate ® (romiplostim), LUMAKRAS ® /LUMYKRASTM (sotorasib), AMJEVITA ® /AMGEVITATM (adalimumab), Repatha ® (evolocumab), KYPROLIS ® (carfilzomib) and Vectibix ® (panitumumab). ◦ Ex-U.S. volume grew 22%, including 47% volume growth in the Asia Pacific region. • GAAP earnings per sha”
AMGEN INC terminated Bridge Credit Facility with Citibank, N.A., Bank of America, N.A., and other lenders valued at $28.5 billion bridge credit facility terminated (effective 2023-03-09).
“On March 9, 2023, we elected to terminate all remaining outstanding commitments under our Bridge Credit Facility and terminate the Bridge Credit Facility in its entirety in accordance with its terms.”
AMGEN INC entered into Third Amended and Restated Revolving Credit Agreement with Citibank, N.A., JPMorgan Chase Bank, N.A., and other banks valued at $4.0 billion revolving credit facility (effective 2023-03-09).
“On March 9, 2023, Amgen Inc. (the “Company”) entered into a third amended and restated revolving credit agreement with Citibank, N.A., as administrative agent (“Citibank”), JPMorgan Chase Bank, N.A., as syndication agent, and the other banks party thereto (the “Revolving Credit Agreement”), for a total commitment of $4.0 billion.”
AMGEN INC amended Bridge Credit Facility with Citibank, N.A., Bank of America, N.A..
“Following the issuance and sale of the Notes described above, the commitments under the Bridge Credit Facility have been further reduced by the amount corresponding to the Net Cash Proceeds to the Company from the Notes offering.”
AMGEN INC entered into Officer's Certificate with The Bank of New York Mellon Trust Company, N.A. valued at $24,000,000,000 aggregate principal amount (effective 2023-03-02).
“On March 2, 2023, Amgen Inc. (the “Company”) issued and sold $2,000,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2025 (the “2025 Notes”), $1,500,000,000 aggregate principal amount of the Company’s 5.507% Senior Notes due 2026 (the “2026 Notes”), $3,750,000,000 aggregate principal amount of the Company’s 5.150% Senior Notes due 2028 (the “2028 Notes”), $2,750,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2030 (the “2030 Notes”), $4,250,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2033 (the “2033 Notes”), $2,750,000,000 aggregate principal amount of the Company’s 5.600% Senior Notes due 2043 (the “2043 Notes”), $4,250,000,000 aggregate principal amount of the Company’s 5.650% Senior Notes due 2053 (the “2053 Notes”) and $2,750,000,000 aggregate principal amount of the Company’s 5.750% Senior Notes due 2063 (the “2063 Notes” and, together with the 2025 Notes, the 2026 Notes, the 2028 Notes, the 203”
AMGEN INC entered into Underwriting Agreement with Citigroup Global Markets Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC and Mizuho Securities USA LLC, as representatives of the several underwriters valued at $2,000,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2025, $1,500,000, (effective 2023-02-15).
“On February 15, 2023, Amgen Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein (the “Underwriters”), to issue and sell to the Underwriters $2,000,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2025 (the “2025 Notes”), $1,500,000,000 aggregate principal amount of the Company’s 5.507% Senior Notes due 2026 (the “2026 Notes”), $3,750,000,000 aggregate principal amount of the Company’s 5.150% Senior Notes due 2028 (the “2028 Notes”), $2,750,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2030 (the “2030 Notes”), $4,250,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2033 (the “2033 Notes”), $2,750,000,000 aggregate principal amount of the Company’s 5.600% Senior Notes due 2043 (the “2043 Notes”)”
AMGEN INC updated its 2023 guidance (initiated).
“AMGEN ALSO PROVIDES 2023 GUIDANCE EXCLUDING ANY CONTRIBUTION FROM THE ANNOUNCED ACQUISITION OF HORIZON THERAPEUTICS”
AMGEN INC reported the year ended December 31, 2022 results: revenue $26.3 billion, EPS $12.11.
“For the full year, total revenues increased 1% to $26.3 billion”
AMGEN INC reported the three months ended December 31, 2022 results: revenue $6.8 billion, EPS $3.00.
“For the fourth quarter, total revenues were $6.8 billion, largely unchanged from Q4 2021.”
AMGEN INC entered into Term Loan Credit Agreement with Citibank, N.A., Bank of America, N.A., Goldman Sachs Bank USA, Mizuho Bank, Ltd. valued at $4,000,000,000 term loan credit facility with two tranches: $2,000,000,000 18-month and $2,000,000,0 (effective 2022-12-22).
“Term Loan Credit Facility On December 22, 2022 (the “ Effective Date ”), Amgen Inc. (“ Amgen ”), Citibank, N.A. (“ Citibank ”), as administrative agent, Bank of America, N.A. (“ Bank of America ”), as syndication agent, Citibank, Bank of America, Goldman Sachs Bank USA and Mizuho Bank, Ltd. as lead arrangers and book runners, and Goldman Sachs Bank USA and Mizuho Bank, Ltd. as documentation agents entered into a Term Loan Credit Agreement (the “ Term Loan Credit Agreement ”). The Term Loan Credit Agreement provides for a (1) a $2,000,000,000 18-month term loan tranche (the “ 18-Month Tranche ”) and (2) a $2,000,000,000 3-year term loan tranche (the “ 3-Year Tranche ”, and together with the 18-Month Tranche, the “ Term Loan Credit Facility ”), with the commitments under the Bridge Credit Agreement entered into by Amgen, as borrower, Citibank, as administrative agent, Bank of America, as syndication agent, and Citibank and Bank of America as lead arrangers and book runners, on December 1”
AMGEN INC incurred credit facility.
“On December 12, 2022, Amgen entered into the Bridge Credit Agreement as described under Item 1.01 above.”
AMGEN INC entered into Transaction Agreement with Horizon Therapeutics plc valued at $116.50 in cash per ordinary share (effective 2022-12-11).
“On December 12, 2022, Amgen Inc., a Delaware corporation (“ Amgen ”), issued an announcement (the “ Rule 2.7 Announcement ”) pursuant to Rule 2.7 of the Irish Takeover Panel Act 1997, Takeover Rules, 2022 (the “ Irish Takeover Rules ”) disclosing that the respective boards of directors of Amgen and Horizon Therapeutics plc, an Irish public limited company (“ Horizon ”), had reached an agreement on the terms of a cash offer for Horizon by Pillartree Limited, a newly formed private limited company wholly owned by Amgen (“ Acquirer Sub ”), pursuant to which Acquirer Sub will acquire the entire issued and to be issued ordinary share capital of Horizon (such proposed offer, the “ Acquisition ”), for $116.50 in cash per ordinary share (the “ Consideration ”), nominal value $0.0001 per share, of Horizon (each, a “ Horizon Share ”).”
AMGEN INC reported third quarter of 2022 results: revenue $6.7 billion. Guidance lowered.
“Total revenues decreased 1% to $6.7 billion in comparison to the third quarter of 2021”
Michael V. Drake was appointed as director at AMGEN INC.
“On August 3, 2022, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed Michael V. Drake as a director of the Company, effective immediately.”
S. Omar Ishrak was appointed as director at AMGEN INC.
“On July 29, 2021, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed S. Omar Ishrak as a director of the Company, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.